Rabies virus-based vaccines elicit neutralizing antibodies, poly-functional CD8+ T cell, and protect rhesus macaques from AIDS-like disease after SIVmac251 challenge

Vaccine

Volumn 28, Issue 2, 2009, Pages 299-308

  Faul, Elizabeth J ^a,b   Aye, Pyone P ^c   Papaneri, Amy B ^a,b   Pahar, Bapi ^c   McGettigan, James P ^a,b   Schiro, Faith ^c   Chervoneva, Inna ^b   Montefiori, David C ^d   Lackner, Andrew A ^c   Schnell, Matthias J ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

HIV 1; Rabies virus; Rhabdovirus; SIVmac251; Vaccine

Indexed keywords

EPITOPE; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; POL PROTEIN; RABIES VACCINE; RETROVIRUS VECTOR; SIV MAC 239; SIV MAC 251; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFICACY; FEMALE; IMMUNOSTIMULATION; MALE; MEMORY T LYMPHOCYTE; MUCOSA; NONHUMAN; PRIORITY JOURNAL; RABIES VIRUS; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; TREATMENT OUTCOME; VIRUS LOAD;

ANIMALS; ANTIBODIES, NEUTRALIZING; CD8-POSITIVE T-LYMPHOCYTES; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; MACACA MULATTA; RABIES VIRUS; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 70649094217     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.10.051     Document Type: Article

References (46)

1. Duerr A., Wasserheit J.N., and Corey L. HIV vaccines: new frontiers in vaccine development. Clin Infect Dis 43 August (4) (2006) 500-511
2. Buchbinder S.P., Mehrotra D.V., Duerr A., Fitzgerald D.W., Mogg R., Li D., et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372 November (9653) (2008) 1881-1893
3. McElrath M.J., De Rosa S.C., Moodie Z., Dubey S., Kierstead L., Janes H., et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 372 November (9653) (2008) 1894-1905
4. Koff W.C., Johnson P.R., Watkins D.I., Burton D.R., Lifson J.D., Hasenkrug K.J., et al. HIV vaccine design: insights from live attenuated SIV vaccines. Nat Immunol 7 January (1) (2006) 19-23
5. McKenna P.M., Koser M.L., Carlson K.R., Montefiori D.C., Letvin N.L., Papaneri A.B., et al. Highly attenuated rabies virus-based vaccine vectors expressing simian-human immunodeficiency virus89.6P Env and simian immunodeficiency virusmac239 Gag are safe in rhesus macaques and protect from an AIDS-like disease. J Infect Dis 195 April (7) (2007) 980-988
6. Faber M., Lamirande E.W., Roberts A., Rice A.B., Koprowski H., Dietzschold B., et al. A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies. J Gen Virol 86 May (Pt 5) (2005) 1435-1440
7. McGettigan J.P., Pomerantz R.J., Siler C.A., McKenna P.M., Foley H.D., Dietzschold B., et al. Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 gag have greatly reduced pathogenicity but are highly immunogenic. J Virol 77 January (1) (2003) 237-244
8. Siler C.A., McGettigan J.P., Dietzschold B., Herrine S.K., Dubuisson J., Pomerantz R.J., et al. Live and killed rhabdovirus-based vectors as potential hepatitis C vaccines. Virology 292 January (1) (2002) 24-34
9. Ambrose Z., KewalRamani V.N., Bieniasz P.D., and Hatziioannou T. HIV/AIDS: in search of an animal model. Trends Biotechnol 25 August (8) (2007) 333-337
10. Kestler H., Kodama T., Ringler D., Marthas M., Pedersen N., Lackner A., et al. Induction of AIDS in rhesus monkeys by molecularly cloned simian immunodeficiency virus. Science 248 June (4959) (1990) 1109-1112
11. Knapp L.A., Lehmann E., Piekarczyk M.S., Urvater J.A., and Watkins D.I. A high frequency of Mamu-A*01 in the rhesus macaque detected by polymerase chain reaction with sequence-specific primers and direct sequencing. Tissue Antigens 50 December (6) (1997) 657-661
12. Smith S.M., Mefford M., Sodora D., Klase Z., Singh M., Alexander N., et al. Topical estrogen protects against SIV vaginal transmission without evidence of systemic effect. AIDS 18 August (12) (2004) 1637-1643
13. Veazey R.S., Mansfield K.G., Tham I.C., Carville A.C., Shvetz D.E., Forand A.E., et al. Dynamics of CCR5 expression by CD4(+) T cells in lymphoid tissues during simian immunodeficiency virus infection. J Virol 74 December (23) (2000) 11001-11007
14. Veazey R.S., Tham I.C., Mansfield K.G., DeMaria M., Forand A.E., Shvetz D.E., et al. Identifying the target cell in primary simian immunodeficiency virus (SIV) infection: highly activated memory CD4(+) T cells are rapidly eliminated in early SIV infection in vivo. J Virol 74 January (1) (2000) 57-64
15. Pahar B., Li J., Rourke T., Miller C.J., and McChesney M.B. Detection of antigen-specific T cell interferon gamma expression by ELISPOT and cytokine flow cytometry assays in rhesus macaques. J Immunol Methods 282 November (1-2) (2003) 103-115
16. Pahar B., Wang X., Dufour J., Lackner A.A., and Veazey R.S. Virus-specific T cell responses in macaques acutely infected with SHIV(sf162p3). Virology 363 June (1) (2007) 36-47
17. Veazey R.S., Klasse P.J., Ketas T.J., Reeves J.D., Piatak Jr. M., Kunstman K., et al. Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection. J Exp Med 198 November (10) (2003) 1551-1562
18. Montefiori D.C. Evaluating neutralizing antibodies against HIV, SIV and SHIV in luciferase reporter gene assays. In: Coligan J.E., Kruisbeek A.M., Margulies D.H., Shevach E.M.W., Strober M.W., and Coico R. (Eds). Current protocols in immunology (2004)
19. Brandt S.M., Mariani R., Holland A.U., Hope T.J., and Landau N.R. Association of chemokine-mediated block to HIV entry with coreceptor internalization. J Biol Chem 277 May (19) (2002) 17291-17299
20. Li M., Gao F., Mascola J.R., Stamatatos L., Polonis V.R., Koutsoukos M., et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 79 August (16) (2005) 10108-10125
21. Vonesh E.F., and Chinchilli V.M. Linear and nonlinear models for the analysis of repeated measurements (1997), Marcel Dekker, New York, NY
22. Verbeke G., and Molenberghs G. Linear mixed models for longitudinal data (2000), Springer-Verlag, New York
23. Hommel G. A comparison of two modified Bonferroni procedures. Biometrika 75 (1988) 383-386
24. Maness N.J., Yant L.J., Chung C., Loffredo J.T., Friedrich T.C., Piaskowski S.M., et al. Comprehensive immunological evaluation reveals surprisingly few differences between elite controller and progressor Mamu-B*17-positive Simian immunodeficiency virus-infected rhesus macaques. J Virol 82 June (11) (2008) 5245-5254
25. mac239 replication. J Virol 80 May (10) (2006) 5074-5077
26. + memory T cells by human immunodeficiency virus type 1: evidence for a role in the selective T-cell functional defects observed in infected individuals. Proc Natl Acad Sci USA 87 August (16) (1990) 6058-6062
27. Chakraborty R., Morel A.S., Sutton J.K., Appay V., Ripley R.M., Dong T., et al. Correlates of delayed disease progression in HIV-1-infected Kenyan children. J Immunol 174 June (12) (2005) 8191-8199
28. Betts M.R., Nason M.C., West S.M., De Rosa S.C., Migueles S.A., Abraham J., et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107 June (12) (2006) 4781-4789
29. Darrah P.A., Patel D.T., De Luca P.M., Lindsay R.W., Davey D.F., Flynn B.J., et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 13 July (7) (2007) 843-850
30. Stahl-Hennig C., Steinman R.M., Tenner-Racz K., Pope M., Stolte N., Matz-Rensing K., et al. Rapid infection of oral mucosal-associated lymphoid tissue with simian immunodeficiency virus. Science 285 August (5431) (1999) 1261-1265
31. Veazey R.S., DeMaria M., Chalifoux L.V., Shvetz D.E., Pauley D.R., Knight H.L., et al. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science 280 April (5362) (1998) 427-431
32. mac251 mucosal challenge. J Virol 82 November (21) (2008) 10911-10921
33. Gaschen B., Taylor J., Yusim K., Foley B., Gao F., Lang D., et al. Diversity considerations in HIV-1 vaccine selection. Science 296 June (5577) (2002) 2354-2360
34. Mascola J.R., Stiegler G., VanCott T.C., Katinger H., Carpenter C.B., Hanson C.E., et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 6 February (2) (2000) 207-210
35. Borrow P., Lewicki H., Hahn B.H., Shaw G.M., and Oldstone M.B. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 68 September (9) (1994) 6103-6110
36. Koup R.A., Safrit J.T., Cao Y., Andrews C.A., McLeod G., Borkowsky W., et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 68 July (7) (1994) 4650-4655
37. Jin X., Bauer D.E., Tuttleton S.E., Lewin S., Gettie A., Blanchard J., et al. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 189 March (6) (1999) 991-998
38. Schmitz J.E., Kuroda M.J., Santra S., Sasseville V.G., Simon M.A., Lifton M.A., et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283 February (5403) (1999) 857-860
39. Sodora D.L., Allan J.S., Apetrei C., Brenchley J.M., Douek D.C., Else J.G., et al. Toward an AIDS vaccine: lessons from natural simian immunodeficiency virus infections of African nonhuman primate hosts. Nat Med 15 August (8) (2009) 861-865
40. mac239. J Virol 76 July (14) (2002) 7187-7202
41. Liu J., O'Brien K.L., Lynch D.M., Simmons N.L., La Porte A., Riggs A.M., et al. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 457 January (7225) (2009) 87-91
42. Ling B., Veazey R.S., Hart M., Lackner A.A., Kuroda M., Pahar B., et al. Early restoration of mucosal CD4 memory CCR5 T cells in the gut of SIV-infected rhesus predicts long term non-progression. AIDS 21 November (18) (2007) 2377-2385
43. Pandrea I.V., Gautam R., Ribeiro R.M., Brenchley J.M., Butler I.F., Pattison M., et al. Acute loss of intestinal CD4+ T cells is not predictive of simian immunodeficiency virus virulence. J Immunol 179 September (5) (2007) 3035-3046
44. Gordon S.N., Klatt N.R., Bosinger S.E., Brenchley J.M., Milush J.M., Engram J.C., et al. Severe depletion of mucosal CD4+ T cells in AIDS-free simian immunodeficiency virus-infected sooty mangabeys. J Immunol 179 September (5) (2007) 3026-3034
45. Silvestri G., Paiardini M., Pandrea I., Lederman M.M., and Sodora D.L. Understanding the benign nature of SIV infection in natural hosts. J Clin Invest 117 November (11) (2007) 3148-3154
46. Schell J., Rose N.F., Fazo N., Marx P.A., Hunter M., Ramsburg E., et al. Long-term vaccine protection from AIDS and clearance of viral DNA following SHIV89.6P challenge. Vaccine 27 February (7) (2009) 979-986